A KRAS mutation was demonstrated in the primary tumour of 15 patients (6 good responders and 9 poor responders), and KRAS wild-type in the primary tumour of 19 patients (11 good responders and 8 poor responders). The gene discussed is KRAS; the disease is neoplasm.